-
Z-VDVAD-FMK in Apoptosis and Pyroptosis Assays
2026-08-17
Z-VDVAD-FMK is a cell-permeable, irreversible caspase-2–directed tool for separating mitochondrial apoptosis from downstream caspase signaling. This workflow also shows how to use it as a mechanistic comparator—not a caspase-1 substitute—when studying HOXC8-linked pyroptosis in lung cancer models.
-
Probenecid in Reliable Cell Assays
2026-08-17
Learn how Probenecid (SKU B2014) can help investigators distinguish transporter-mediated drug resistance from intrinsic cytotoxicity in cell-based assays. This scenario-driven guide covers formulation, controls, protocol optimization, interpretation, and practical vendor-selection criteria.
-
Chlamydial Vesicles Deliver OmpA to Mitochondria
2026-08-16
Mesesan et al. show that Chlamydia trachomatis uses bacteria-derived membrane vesicles to transport the β-barrel protein OmpA to host mitochondria, where it engages BAK and suppresses mitochondrial apoptosis. The study links vesicle-mediated organelle delivery to pathogen survival and provides a framework for distinguishing upstream mitochondrial control from downstream caspase activity inhibition.
-
Z-VAD-FMK Workflows for Apoptosis Research
2026-08-15
Build cleaner apoptosis experiments with Z-VAD-FMK, from caspase-dependence tests in THP-1 and Jurkat cells to mechanistic controls in small cell lung cancer models. The workflow also shows how to distinguish caspase-mediated apoptosis from ZBP1-associated, non-apoptotic cell death described in recent spliceosome research.
-
Q-VD-OPh Workflows for Caspase-Driven Cell Death
2026-08-14
Q-VD-OPh is a cell-permeable pan-caspase inhibitor for separating caspase-dependent apoptosis from lysosomal and other parallel death programs. This practical guide covers assay design, cryopreservation support, neurodegenerative disease models, dosing logic, and troubleshooting without treating caspase blockade as proof of a single death mechanism.
-
Drug Response Assays: Viability, Killing, Timing
2026-08-14
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response outcomes. The work provides a practical framework for separating cytostatic effects from cytotoxicity and for interpreting how response timing can alter conclusions from in vitro cancer assays.
-
Saquinavir Workflows for Protease and Membrane Studies
2026-08-13
Build more informative Saquinavir experiments by pairing direct HIV protease inhibition assays with biomimetic membrane-partitioning measurements. This workflow shows when IAM LC or LEKC is the better choice, how to control DMSO and pH effects, and how to troubleshoot weak or misleading signals.
-
10058-F4: A Better Way to Read c-Myc Biology
2026-08-13
10058-F4 is a c-Myc-Max dimerization inhibitor that can reveal how transcriptional disruption becomes cell-cycle arrest, mitochondrial apoptosis, or differentiation. This article presents an assay-centered framework connecting c-Myc perturbation with the APEX2–TERT findings while clearly separating established evidence from testable hypotheses.
-
Optimized hiPSC Differentiation for Functional Platelets
2026-08-12
A 2026 study in Stem Cell Reviews and Reports presents an optimized differentiation scheme for producing megakaryocytes and functional platelets from human induced pluripotent stem cells. By increasing embryoid body input, using human platelet lysate, replacing selected cytokines with small molecules, and promoting megakaryocyte maturation, the protocol improved yield, shortened production time, and reduced reported costs.
-
Fluo-4 AM for Mechanotransduction Assays
2026-08-12
Connect fiber-density engineering with live-cell calcium readouts using a sensitive, no-wash workflow. The approach supports both mechanotransduction studies in annulus fibrosus cells and scalable GPCR inhibitor or agonist screening.
-
Berbamine hydrochloride Workflows for Ferroptosis
2026-08-11
Build a controlled workflow for testing Berbamine hydrochloride across leukemia and hepatocellular carcinoma models, while separating pathway modulation from ferroptotic cell death. The approach combines product-handling guidance with the METTL16–SENP3–LTF findings to improve assay design, comparison, and troubleshooting.
-
Pol II Degradation and Transcription-Independent Death
2026-08-11
The preprint argues that targeted degradation of RNA polymerase II can activate cell death without requiring global transcriptional shutdown, separating Pol II loss from the conventional assumption that death follows transcriptional collapse. This distinction provides a useful framework for interpreting apoptosis mechanisms and for designing experiments that independently measure protein degradation, transcription, and cell-death execution.
-
Entinostat (MS-275) Workflow for Cancer Assays
2026-08-10
Entinostat (MS-275) combines HDAC1/3-biased epigenetic modulation with a practical platform for separating growth arrest from true cell killing. This workflow shows how to optimize dosing, pair viability with death and acetylation readouts, and translate findings cautiously into retinoblastoma research and solid tumor studies.
-
JNJ-26854165 (Serdemetan): p53 Research Guide
2026-08-09
JNJ-26854165, also called Serdemetan, is a small-molecule HDM2 ubiquitin ligase antagonist for preclinical cancer research. Its reported activity includes p53 pathway modulation, cell-proliferation inhibition, endothelial migration inhibition, and enhancement of radiation-induced tumor growth delay in xenografts.
-
Cy3 TSA Fluorescence System Kit Workflow
2026-08-08
Build a sensitive, microscopy-ready workflow for IHC, ICC, and ISH when conventional fluorescence produces weak or ambiguous signals. This guide connects Cy3 tyramide deposition with spatial proteomics, showing where the kit adds localization confidence and where it should not be mistaken for a proteomic measurement.